Clinical Utility of Deutetrabenazine as a Treatment Option for Chorea Associated with Huntington’s Disease and Tardive Dyskinesia

IF 2.8 3区医学 Q1 Pharmacology, Toxicology and Pharmaceutics

Therapeutics and Clinical Risk Management Pub Date : 2023-12-01 DOI:10.2147/tcrm.s279332

Samuel Frank, Aljoharah Alakkas

引用次数: 0

Abstract

Abstract: Deutetrabenazine (DTBZ) is used for the treatment of tardive dyskinesia (TD) and chorea in Huntington’s Disease (HD). Four pivotal clinical trials showed the efficacy of DTBZ in these conditions. Long term follow-up studies confirmed evidence of overall safety and continued efficacy of this drug. Indirect comparisons revealed relative superiority of DTBZ over TBZ in terms of safety, but direct comparisons of safety and efficacy between the VMAT2 and dopamine blocking agents is lacking. Deutetrabenazine is safe and effective in the treatment of TD and chorea in HD in doses up to 72 mg daily and for up to three years in duration.

Keywords: chorea, tardive dyskinesia, hyperkinetic movement disorders, VMAT2 inhibitors

查看原文本刊更多论文

二氘苯那嗪作为亨廷顿舞蹈病和迟发性运动障碍相关舞蹈病的治疗选择的临床应用

摘要:二氘苯那嗪(DTBZ)用于治疗亨廷顿舞蹈病(HD)的迟发性运动障碍(TD)和舞蹈病。四项关键的临床试验显示了DTBZ在这些情况下的疗效。长期随访研究证实了该药物总体安全性和持续有效性的证据。间接比较显示DTBZ相对于TBZ在安全性方面的相对优势，但缺乏VMAT2和多巴胺阻断剂之间的安全性和有效性的直接比较。Deutetrabenazine在治疗腹泻和舞蹈病方面是安全有效的，每日剂量高达72毫克，持续时间长达三年。关键词:舞蹈病，迟发性运动障碍，多动运动障碍，VMAT2抑制剂

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Therapeutics and Clinical Risk Management HEALTH CARE SCIENCES & SERVICES-

CiteScore

5.30

自引率

3.60%

发文量

139

审稿时长

16 weeks

期刊介绍： Therapeutics and Clinical Risk Management is an international, peer-reviewed journal of clinical therapeutics and risk management, focusing on concise rapid reporting of clinical studies in all therapeutic areas, outcomes, safety, and programs for the effective, safe, and sustained use of medicines, therapeutic and surgical interventions in all clinical areas. The journal welcomes submissions covering original research, clinical and epidemiological studies, reviews, guidelines, expert opinion and commentary. The journal will consider case reports but only if they make a valuable and original contribution to the literature. As of 18th March 2019, Therapeutics and Clinical Risk Management will no longer consider meta-analyses for publication. The journal does not accept study protocols, animal-based or cell line-based studies.